US Patent

US9351923 — Extended-release composition comprising a somatostatin derivative in microparticles

Formulation · Assigned to Novartis AG · Expires 2028-05-23 · 2y remaining

Vulnerability score 55/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects an extended-release composition of a somatostatin derivative in microparticles made by Novartis AG.

USPTO Abstract

The present invention relates to improved microparticles comprising a somatostatin analog, a process of making said microparticles and to pharmaceutical compositions comprising the same.

Drugs covered by this patent

pasireotide-pamoate (PASIREOTIDE PAMOATE)

Patent Metadata

Patent number: US9351923
Jurisdiction: US
Classification: Formulation
Expires: 2028-05-23
Drug substance claim: No
Drug product claim: Yes
Assignee: Novartis AG
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.